A Phase 1/2 interventional study of Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell) and Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell) in Hand, Foot, and Mouth Disease (HFMD) and Herpangina, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Sinovac Biotech Co., Ltd · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.
Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 18th registered.
59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.
Browse Hand, Foot and Mouth Disease studies →4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo–71 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in Vietnam
Ages 6 mo–71 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo–71 mo · Healthy volunteers
Sinovac Biotech Co., Ltd
Ages 6 mo–18 yrs
By country, each count listing its studies:
Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 6 Months to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 5 · Phase 4 6
First in 2011; this study’s year is marked. 1 started in 2025.
This study's enrollment of 552 is above the median of 467 across 50 interventional studies indexed under Hand, Foot and Mouth Disease.
Median enrollment 744 across the 15 interventional studies, 600 across the 5 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.
1 of the studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07793175Sinovac Biotech Co., LtdBridging Clinical Trial of EV71 Vaccine in Vietnamese Children | 2027-01-09 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial aims to assess the tolerability, safety, and immunogenicity of the tetravalent inactivated enterovirus vaccine in adults and children aged 6 months to 12 years. The main questions it aims to answer are:
In Phase I, researchers will compare the safety of the investigational vaccine at low, medium, and high doses with the control vaccine; in Phase II, they will compare the safety and immunogenicity (including immune persistence) of the investigational vaccine at medium and high doses with the control vaccine.
Procedure:
Both Phase I and Phase II clinical trials adopt a randomized, double-blind, controlled design.
For Phase I, 192 healthy participants are planned to be enrolled, including 48 adults aged 18-59, 48 children aged 6-12, 48 children aged 24-71 months, and 48 children aged 6-23 months. They will receive two doses of the experimental vaccine or EV71 vaccine (for those aged 6-71 months) / placebo (for those aged 6-12 and 18-59) in the order of low-dose, medium-dose, and high-dose. The interval between the two doses is one month. Enrollment will follow the sequence of adults aged 18-59, children aged 6-12, children aged 24-71 months, and children aged 6-23 months. Within each dosage stage, there will be 16 participants from each age group, and they will receive the experimental vaccine or control EV71 vaccine / placebo in a 3:1 ratio.
The dose escalation principle within each age group is low-dose, medium-dose, and high-dose. Based on the occurrence of AEs and clinical laboratory indicators, the next higher dose stage can only be initiated after a 0-7 day safety observation period following the first dose of the lower dose stage and confirmation of safety. The sequential enrollment principle across age groups is adults aged 18-59, children aged 6-12, children aged 24-71 months, and children aged 6-23 months. For each dose, after completing the 0-7 day safety observation period following the first dose and confirming safety, the next age group can proceed with enrollment for that dose.
For adults aged 18-59 and children aged 6-12, venous blood and urine samples will be collected before each dose and on the 3rd day after vaccination for blood routine tests (about 2.0 ml of venous blood), blood biochemistry tests (about 2.0-3.0 ml of venous blood), and urine routine tests (about 2.0-10.0 ml of urine) to evaluate vaccine safety. For children aged 24-71 months, only about 2.0-3.0 ml of venous blood will be collected at the corresponding time points for blood biochemistry tests.
If more than 10% of participants in each dose stage of the 24-71 month age group experience abnormal laboratory test results related to the investigational vaccine and of clinical significance after the first dose, then for the corresponding dose stage in the 6-23 month age group, blood routine tests (about 1.0 ml of venous blood), blood biochemistry tests (about 2.0-3.0 ml of venous blood), and urine routine tests (about 2.0-10.0 ml of urine) will be conducted on the 3rd day after the first dose, before the second dose, and on the 3rd day after the second dose.
After obtaining safety data for all participants in Phase I for 30 days after the completion of vaccination, the data will be analyzed, and a safety analysis report will be submitted to the Data Monitoring Committee (DMC) and Ethical Committee (EC) for review. Only after confirming safety can the Phase II clinical trial be initiated.
For Phase II, 360 healthy participants aged 6 months to 12 years are planned to be enrolled, including 120 children aged 6-23 months, 120 children aged 24-71 months, and 120 children aged 6-12. Participants in each age group will be randomly assigned to the medium-dose and high-dose groups of the investigational vaccine and the control group in a 1:1:1 ratio, receiving two doses of the investigational vaccine or EV71 vaccine (for those aged 6-71 months) / placebo (for those aged 6-12) with a one-month interval. With the day of the first dose as Day 0, all participants in Phase II will have about 3.0 ml of venous blood collected on Days 0, 60, and 210 to separate serum for EV71, CA16, CA10, and CA6 neutralizing antibody tests, evaluating the vaccine's immunogenicity and immune persistence.
All participants in both Phase I and Phase II will be observed for immediate reactions within 30 minutes after each dose, and solicited local and systemic AEs will be collected for 0-7 days, while unsolicited AEs will be collected for 0-30 days. Additionally, SAE monitoring will be conducted from the start of vaccination until 6 months after the completion of the vaccination schedule. Furthermore, for fertile participants in the Phase I clinical trial, during the trial and after the first dose, pregnancy events of female participants themselves or the partners of male participants will be collected through a combination of active follow-up by researchers and self-reporting by participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
laboratory abnormalities beyond the reference range in clinical laboratory tests (only applicable to Phase I clinical trial participants):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)(Only for phase Ⅰ)
Biological: Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Medium-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Biological: Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
High-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Biological: High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
EV71 vaccine (for ages 6-71 months)
Biological: EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)
placebo (for ages 6-12 years)
Biological: placebo (for ages 6-12 years)
Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ)
Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)
placebo (for ages 6-12 years)
Phase Ⅰ:The safety of the investigational vaccine in the target population based on AR.
Incidence rate of AR from vaccination onset to 30 days post-full immunization in children aged 6 months to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the seropositive conversion rates of the investigational vaccine in the target population.
The seropositive conversion rates of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 months to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the geometric mean titer (GMT) of the investigational vaccine in the target population.
The GMT of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 months to 12 years.
Time frame: 60 days
phase Ⅰ:Evaluate the safety of the investigational vaccine in the target population based on adverse events (AEs).
Incidence rate of adverse reactions (ARs) from vaccination onset to 30 days post full immunization in adults aged 18-59.
Time frame: 60 days
phase Ⅰ: Evaluate the safety of the investigational vaccine in the target population based on adverse events (AEs) in adults aged 18-59.
phase Ⅰ: Incidence rate of serious adverse events (SAEs) from vaccination onset to 6 months post full immunization in adults aged 18-59.
Time frame: 7 monthes
phase Ⅰ: Evaluate the safety of the investigational vaccine in the target population based on AEs in children aged 6 months to 12 years.
phase Ⅰ: Incidence rate of serious adverse events (SAEs) from vaccination onset to 6 months post full immunization in children aged 6 months to 12 years.
Time frame: 7 monthes
phase Ⅰ:Evaluate the safety of the investigational vaccine in adults aged 18-59 and children aged 6-12 based on laboratory abnormalities.
Incidence rate of clinically significant abnormalities in blood biochemistry, blood routine, and urinalysis indicators on the 3rd day after each dose in adults aged 18-59 and children aged 6-12.
Time frame: 3 days
phase Ⅰ:Evaluate the safety of the investigational vaccine in children aged 24-71 months based on laboratory abnormalities.
phase Ⅰ:Incidence rate of clinically significant abnormalities in blood biochemistry indicators on the 3rd day after each dose in children aged 24-71 months.
Time frame: 3 days
phase Ⅱ:Evaluate the seropositive rate of the investigational vaccine.
phase Ⅱ: Seropositive rate and of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 months to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate Geometric mean increase (GMI) of the investigational vaccine in children aged 6 months to 12 years.
Phase Ⅱ: GMI of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 months to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the seroconversion rate of the investigational vaccine in children aged 6 to 71 months.
Phase Ⅱ:Seroconversion rate of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 71 months.
Time frame: 60 days
Phase Ⅱ:Evaluate the seropositive rate of the investigational vaccine in children aged 6 to 71 months.
Phase Ⅱ:Seropositive rate of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 71 months.
Time frame: 60 days
Phase Ⅱ:Evaluate the GMT of the investigational vaccine in children aged 6 to 71 months.
Phase Ⅱ: GMT of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 71 months.
Time frame: 60 days
Phase Ⅱ:Evaluate the GMI of the investigational vaccine in children aged 6 to 71 months.
Phase Ⅱ: GMI of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 71 months.
Time frame: 60 days
Phase Ⅱ:Evaluate the seroconversion rate of the investigational vaccine in children aged 6 to 12 years.
Phase Ⅱ:Seroconversion rate of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the seropositive rate of the investigational vaccine in children aged 6 to 12 years
Phase Ⅱ:Seropositive rate of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the GMT of the investigational vaccine in children aged 6 to 12 years.
Phase Ⅱ: GMT of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 12 years.
Time frame: 60 days
Phase Ⅱ:Evaluate the GMI of the investigational vaccine in children aged 6 to 12 years.
Phase Ⅱ: GMI of neutralizing antibodies against EV71, CA16, CA10, and CA6 on the 30th day after full vaccination in children aged 6 to 12 years.
Time frame: 60 days
phase Ⅱ:Evaluate the safety of the investigational vaccine based on AEs.
phase Ⅱ:Incidence rate of ARs from vaccination onset to 30 days post full immunization in children aged 6 months to 12 years.
Time frame: 60 days
phase Ⅱ:Evaluate the safety of the investigational vaccine based on AEs.
phase Ⅱ:Incidence rate of SAEs from vaccination onset to 6 months post full immunization in children aged 6 months to 12 years.
Time frame: 7 monthes
Phase Ⅱ:Evaluate the immune persistence of the investigational vaccine via seropositive rate of neutralizing antibodies.
Phase Ⅱ: Seropositive rate of neutralizing antibodies against EV71, CA16, CA10, and CA6 at 6 months post full immunization in children aged 6 months to 12 years.
Time frame: 7 monthes
Phase Ⅱ:Evaluate the immune persistence of the investigational vaccine via GMT of neutralizing antibodies.
Phase Ⅱ: GMT of neutralizing antibodies against EV71, CA16, CA10, and CA6 at 6 months post full immunization in children aged 6 months to 12 years.
Time frame: 7 monthes
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Dec 2025, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EV71
Hand, Foot and Mouth Disease →